2024-10-16 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and manufactures prescription medicines, vaccines, and animal health products.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** MRK has a cumulative return of 70.49% compared to the S&P 500 (VOO) with a return of 135.82%. 
* **Relative Lag:** MRK is currently lagging behind the S&P 500 by -65.33%. This represents a relative performance of 19.62% based on historical data.

**2. Recent Price Movement:**

* **Closing Price:** $109.73
* **5-day Moving Average:** $109.32
* **20-day Moving Average:** $113.41
* **60-day Moving Average:** $115.82

**3. Technical Indicators:**

* **RSI:** 28.08, indicating that the stock is currently oversold.
* **PPO:** -0.32, suggesting a downtrend.
* **Delta_Previous_Relative_Divergence:** -15.01, indicating a recent short-term decline in relative performance.
* **Expected Return:** 0.0%, indicating a potential 5-year expected return of 0% compared to the S&P 500.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

The most recent earnings report for the quarter ending 2024-08-05 showed EPS of $2.15, exceeding analyst expectations. Revenue came in at $16.11B, slightly higher than predicted. 

**5. News & Recent Issues:**

**Market Outlook:** MRK stock has been under pressure in recent months due to concerns regarding its performance and the broader market volatility. Analysts are divided on its short-term prospects, with some expressing cautious optimism while others remain neutral. 

**Analyst Opinions:** Several analysts have expressed concerns about the potential impact of generic competition on MRK's key products, specifically Keytruda. However, analysts also acknowledge the strength of its pipeline and its potential for future growth. 

**Performance Highlights:** MRK has a strong track record of innovation and research, with several promising new drug candidates in its pipeline. The company has also made significant investments in its manufacturing capacity and digital initiatives. 

**6. Overall Analysis:**

MRK is currently lagging behind the broader market, with its recent performance negatively impacted by several factors. Technical indicators suggest a potential oversold condition, while analysts express mixed sentiments regarding its short-term prospects.  However, the company's strong fundamentals, innovative pipeline, and market leadership position in several therapeutic areas suggest that it has the potential for long-term growth. 

**7. Conclusion:**

Overall, MRK presents a mixed investment case. While the current market environment and recent performance are concerning, the company's strong fundamentals and future potential offer a potential for long-term growth. Investors should carefully consider the risks and potential rewards before making any investment decisions.

**Disclaimer:** This report is for informational purposes only and should not be considered as investment advice. It is essential to conduct thorough research and consult with a qualified financial advisor before making any investment decisions. 
